Michelle Fransen Shares A Historical Review on Plasma-Derived Medicinal Products
Michelle Fransen, Director, Lead for Study Management at Plasma Protein Therapeutics Association (PPTA), shared on LinkedIn:
”I am thrilled to share that Dr. Toby Simon and I had our article, “Source plasma apheresis and plasma-derived medicinal products: a historical review” published in the most recent issue Annals of Blood.
This paper, which can be found here, outlines the history of plasmapheresis and PDMP manufacturing which spans more than a century of scientific and clinical innovation.
We believe that understanding this history is more than academic—it underscores how continued innovation, strong regulatory oversight, and a focus on donor health are essential to sustaining a global plasma supply and advancing care for patients with immune deficiencies, coagulation disorders, and other rare diseases.”
Read the full article here.
Article: Source plasma apheresis and plasma-derived medicinal products: a historical review
Authors: Michelle Fransen, Toby Simon
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 22, 2026, 11:35Congratulations to Donald Arnold for Being Recognized with The ISTH 2026 Harold R. Roberts Award
-
Apr 22, 2026, 11:27Prashasti Dahiya: Key Molecular Insights on Thromboinflammation and Angiogenesis in Pediatric Cancer
-
Apr 22, 2026, 11:17Jack Hadfield: Understanding the Immune and Genetic Basis of VITT Post-COVID Vaccines
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors
-
Apr 22, 2026, 07:46Gregory Piazza: Ushering in a New Era in PE Therapy and Improved Clinical Outcomes for Our Patients
-
Apr 22, 2026, 07:40Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
-
Apr 22, 2026, 07:36Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar 61
-
Apr 22, 2026, 07:34Aikati Anastasiou: Advancing Stroke Imaging Insights from the DISTAL Trial
-
Apr 22, 2026, 07:26Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?